A detailed history of Glen Eagle Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 17,807 shares of ABBV stock, worth $3.57 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
17,807
Previous 3,060 481.93%
Holding current value
$3.57 Million
Previous $290 Million 954.45%
% of portfolio
0.56%
Previous 0.24%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $2.28 Million - $2.67 Million
14,747 Added 481.93%
17,807 $3.05 Billion
Q1 2024

Jul 03, 2024

BUY
$159.82 - $182.1 $2.73 Million - $3.11 Million
17,091 New
17,091 $3.11 Billion
Q4 2023

Aug 13, 2024

SELL
$137.6 - $154.97 $22,704 - $25,570
-165 Reduced 0.93%
17,546 $2.72 Billion
Q3 2023

Aug 13, 2024

BUY
$133.59 - $154.65 $58,779 - $68,046
440 Added 2.55%
17,711 $2.64 Billion
Q2 2023

Aug 13, 2024

BUY
$132.51 - $164.9 $100,972 - $125,653
762 Added 4.62%
17,271 $2.33 Billion
Q1 2023

Aug 13, 2024

BUY
$144.61 - $166.54 $82,138 - $94,594
568 Added 3.56%
16,509 $2.63 Billion
Q4 2022

Aug 13, 2024

SELL
$138.31 - $165.87 $5,255 - $6,303
-38 Reduced 0.24%
15,941 $2.58 Billion
Q3 2022

Aug 13, 2024

BUY
$134.21 - $153.93 $22,547 - $25,860
168 Added 1.06%
15,979 $2.14 Billion
Q2 2022

Aug 13, 2024

BUY
$137.62 - $174.96 $28,074 - $35,691
204 Added 1.31%
15,811 $2.42 Billion
Q1 2022

Aug 13, 2024

BUY
$131.98 - $163.75 $38,934 - $48,306
295 Added 1.93%
15,607 $2.53 Billion
Q4 2021

Aug 13, 2024

SELL
$107.43 - $135.93 $26,320 - $33,302
-245 Reduced 1.57%
15,312 $2.07 Billion
Q3 2021

Aug 13, 2024

BUY
$106.4 - $120.78 $208,437 - $236,608
1,959 Added 14.41%
15,557 $1.68 Billion
Q2 2021

Aug 13, 2024

BUY
$105.21 - $117.21 $50,395 - $56,143
479 Added 3.65%
13,598 $1.53 Billion
Q1 2021

Aug 13, 2024

BUY
$102.3 - $112.62 $99,640 - $109,691
974 Added 8.02%
13,119 $1.41 Billion
Q4 2020

Aug 13, 2024

SELL
$80.49 - $108.67 $398,103 - $537,481
-4,946 Reduced 28.94%
12,145 $1.3 Billion
Q3 2020

Aug 13, 2024

BUY
$85.91 - $100.83 $94,844 - $111,316
1,104 Added 9.91%
12,239 $1.07 Billion
Q2 2020

Aug 13, 2024

BUY
$73.37 - $98.18 $240,726 - $322,128
3,281 Added 41.77%
11,135 $1.09 Billion
Q1 2020

Aug 13, 2024

BUY
$64.5 - $97.79 $242,713 - $367,983
3,763 Added 91.98%
7,854 $598 Million
Q4 2019

Aug 13, 2024

BUY
$72.13 - $90.25 $25,389 - $31,768
352 Added 9.41%
4,091 $362 Million
Q3 2019

Aug 13, 2024

SELL
$62.98 - $75.72 $8,250 - $9,919
-131 Reduced 3.39%
3,739 $283 Million
Q2 2019

Aug 13, 2024

BUY
$65.7 - $83.98 $23,192 - $29,644
353 Added 10.04%
3,870 $281 Million
Q1 2019

Aug 13, 2024

SELL
$77.14 - $90.79 $1.05 Million - $1.23 Million
-13,574 Reduced 79.42%
3,517 $283 Million
Q4 2018

Aug 13, 2024

BUY
$77.85 - $96.01 $2,335 - $2,880
30 Added 0.96%
3,161 $291 Million
Q3 2018

Aug 13, 2024

SELL
$88.91 - $98.84 $15,114 - $16,802
-170 Reduced 5.15%
3,131 $296 Million
Q2 2018

Aug 13, 2024

SELL
$89.78 - $106.23 $7.67 Million - $9.08 Million
-85,469 Reduced 96.28%
3,301 $306 Million
Q1 2018

Aug 14, 2024

SELL
$92.01 - $123.21 $1.29 Million - $1.73 Million
-14,031 Reduced 82.1%
3,060 $290 Million
Q1 2018

Aug 13, 2024

BUY
$92.01 - $123.21 $7.92 Million - $10.6 Million
86,096 Added 3219.75%
88,770 $290 Million
Q4 2017

Aug 13, 2024

SELL
$89.56 - $98.21 $15,583 - $17,088
-174 Reduced 6.11%
2,674 $259 Million
Q3 2017

Aug 13, 2024

SELL
$69.85 - $89.22 $994,873 - $1.27 Million
-14,243 Reduced 83.34%
2,848 $253 Million
Q2 2017

Aug 12, 2024

BUY
N/A
2 Added 0.07%
2,872 $208 Million
Q1 2017

Aug 12, 2024

BUY
N/A
2 Added 0.07%
2,870 $187 Million
Q4 2016

Aug 12, 2024

SELL
N/A
-14,223
2,868 $180 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.